New drug duo aims to shrink tough liver tumors
NCT ID NCT05194293
Summary
This study is testing if a combination of two drugs, regorafenib and durvalumab, can shrink tumors in people with high-risk liver cancer before they have surgery. The goal is to see if this pre-surgery treatment makes the cancer easier to remove and helps patients live longer. It is for adults with specific stages of liver cancer who have not had certain other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.